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Background: Previous studies suggested that hypoﬁbrinolysis is associated with increased risk of peripheral
arterial disease. Thrombin activatable ﬁbrinolysis inhibitor (TAFI) has been identiﬁed as an important
inhibitor of ﬁbrinolysis. The aim of our study was to assess the role of TAFI in young patients with peripheral
arterial disease.
Methods: In a single-center case-control study we measured plasma TAFI antigen levels and functional TAFI in
consecutive young patients (men 18-45 years and women 18-55 years) with a ﬁrst manifestation of
peripheral arterial disease and compared these with a population-based control group.
Results: A total of 47 peripheral arterial disease patients and 141 controls (mean age 43) were included. Intact
TAFI antigen levels were signiﬁcantly higher in patients with peripheral arterial disease (112.4±21.1%) than
in controls (104.9±19.9%, p=0.03). The risk of peripheral arterial disease increased with 18% (OR 1.18; CI
1.01-1.34) per 10% increase of TAFI antigen. Functional TAFI levels were slightly higher in patients compared
to controls, however this difference was not signiﬁcant. For individuals with the highest functional TAFI levels,
above the 90th percentile, the increased risk for peripheral arterial disease was most pronounced (OR 3.1;
CI 1.02-9.41).
Conclusion: High TAFI levels are associated with increased risk of premature peripheral arterial disease.
© 2010 Elsevier Ltd. Open access under the Elsevier OA license. Introduction
Previous studieshave reportedassociations betweenhypoﬁbrinolysis
and an increased risk of peripheral arterial disease (PAD) [1,2]. Most
studies on hypoﬁbrinolysis focussed on elevated plasminogen activator
inhibitor-1 (PAI-1) levels and showed association between PAI-1
and PAD [3,4] or symptoms of PAD [5]. Also the functional PAI-1 -675
(4 G/5 G) polymorphism was associated with early thrombotic reocclu-
sions [6].
Thrombin activatable ﬁbrinolysis inhibitor (TAFI) has also been
identiﬁed as an important inhibitor of ﬁbrinolysis [7,8]. Activated TAFI
(TAFIa) exerts its anti-ﬁbrinolytic function by removing the carboxy-
terminal lysine residues of partially degraded ﬁbrin. This results in
a decreased binding and activation of plasminogen and thereby
attenuates ﬁbrinolysis [9,10]. TAFI is activated by thrombin, plasmin or
the thrombin/thrombomodulin complex by a single cleavage at Arg-, Erasmus MC, P.O. Box 2040,
31 33; fax: +31 10 703 58 14.
debruijne@planet.nl
vier OA license. 92. This results in the release of the activation peptide (TAFI-AP) and
exposure of the substrate binding site of TAFIa. TAFIa is thermolabile
due to a spontaneous conformational conversion into an inactive form
(TAFIa(i)), which is sensitive to further proteolytic cleavage.
Several studies have been performed to study TAFI levels in arterial
thrombosis. It has been shown that increased functional TAFI levels
and/or TAFI antigen levels are associated with ischemic stroke [11,12].
The relationship between TAFI levels and the risk of coronary heart
disease is less clear, since several conﬂicting studies have been
reported [13–15]. So far no studies have been performed to assess the
role of TAFI in peripheral arterial disease.
Therefore, the aim of our study was to investigate both antigen
and functional TAFI-levels, including the activation markers TAFI-AP
and TAFIa(i) in young patients with a ﬁrst clinical manifestation of
peripheral arterial disease.
Patients
The “Genetic risk factors for Arterial Thrombosis at young age: the
role of TAFI and other Coagulation factors (ATTAC)” study is a single-
center, case-control study to explore the role of TAFI levels and the
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study were consecutively recruited patients with a ﬁrst-ever ischemic
event due to peripheral arterial disease at the department of Vascular
Surgery of the Erasmus Medical Center Rotterdam in the Netherlands.
The diagnosis PAD was deﬁned as peripheral arterial stenosis
resulting in ischemia, classiﬁed according to the Rutherford criteria
[16]. Patients were eligible for inclusion if they were 18 - 45 years for
males and 18 - 55 years for females. Patients were included one to
three months after the event in order to avoid a possible inﬂuence of
the event or an acute phase response on plasma levels of TAFI and TAFI
activity.
A control group was obtained by asking the patients to bring
a friend, neighbour or partner fulﬁlling the same age criteria but
without a history of arterial thrombosis. Relatives of patients were
not permitted. A detailed clinical history and physical examination,
including arterial pulsations of upper and lower extremities, was
performed in both patients and controls. For this study, 3 age- and
sex-matched controls were randomly selected for each patient.
Information was obtained on cardiovascular risk factors, including
smoking, hypercholesterolemia, diabetes mellitus, hypertension and
family history of cardiovascular disease. Smoking statuswas deﬁned as
never, previous or current smoker. Hypercholesterolemia was deﬁned
as total cholesterol level N5.0 mmol/l or receiving lipid-lowering
treatment on day of the ischemic event. Patientswith amedical history
of diabetes or using either oral anti-diabetic medication or insulin
therapy on day of the event were considered to be diabetics.
Hypertension was deﬁned by a systolic blood pressure ≥140 mm
Hg, and/or diastolic blood pressure ≥90 mmHg or the use of anti-
hypertensive drugs. A positive family history was noted if the patient
had a ﬁrst-degree relative with a history of cardiovascular disease
before the age of 60.
Written informed consent was obtained on enrollment from each
participant, and the study was approved by the Medical Ethics
Committee of ErasmusMC and conducted according to the procedures
of the Declaration of Helsinki.
Methods
Blood was drawn under strictly standardized conditions [17], by
venipuncture in the antecubital vein using the Vacutainer system
(Becton Dickinson, Plymouth, UK). Blood for coagulation studies in
both patients and controls was collected in 3.2% trisodium citrate (9:1
vol/vol). Citrated bloodwas centrifugedwithin one hour at 2,000 g for
10 min at 4 °C. Plasma was additionally centrifuged at 20,000 g for
10 min at 4 °C and stored at -80 °C until analysis.
TAFI antigen levels
Three recently developed sandwich-type ELISAs (i.e. MA-T12D11/
MA-T30E5-HRP, MA-T12D11/MA-T18A8-HRP and MA-T30E5/MA-
17D7-HRP) were used to quantify the plasma levels of TAFI, TAFI
activation peptide (TAFI-AP) and (in)activated TAFI (TAFIa(i)),
respectively [18]. To obtain pooled human plasma, blood samples
(n=21 blood donors) were collected in 4% citrate according to the
guidelines of the blood transfusion centre (Red Cross, Leuven,
Belgium) and plasma was pooled. Either non-activated pooled
human plasma (MA-T12D11/MA-T30E5-HRP ELISA) or activated
pooled human plasma (MA-T12D11/MA-T18A8-HRP and MA-T30E5/
MA-17D7-HRP ELISAs)was used as a standard (1:40 dilution of plasma
in PTAE buffer (PBS pH 7.4 containing 0.002% Tween 80, 1 g/l BSA
and 5 mM EDTA), followed by serial two-fold dilutions up to 1:2560).
For preparation of the standard for the MA-T12D11/MA-T18A8-HRP
and MA-T30E5/MA-17D7-HRP ELISAs, pooled human plasma was
incubatedwith thrombin (20 nM), thrombomodulin (5 nM) and CaCl2
(17 mM) in Hepes buffer at 37 °C for 15 minutes. The reaction wasstopped by addition of H-D-Phe-L-Prolyl-L-arginine chloromethylk-
etone (PPACK, 30 μM ﬁnal concentration).
Plasma samples derived from patients were diluted 1:160 (MA-
T12D11/MA-T30E5-HRP ELISA), 1:80 (MA-T12D11/MA-T18A8-HRP
ELISA) and 1:80 (MA-T30E5/MA-17D7-HRP ELISA). All values of TAFI
and TAFI activation markers are expressed relative to the levels in the
pooled human plasma.
The assay variability of the ELISAs was evaluated using 4 different
plasma samples each assayed 4 times on 4 occasions. The intra-assay
and inter-assay coefﬁcients of variation for MA-T12D11/MA-T30E5-
HRP were 6.2% and 8.3%, respectively, for MA-T12D11/MA-T18A8-
HRP 3.1% and 7.3%, respectively and for MA-T30E5/MA-T17D7-HRP
3.3% and 6.4%, respectively.
The interdilution coefﬁcients of variation were 8.2%, 5.1% and 7.3%
for MA-T12D11/MA-T30E5-HRP, MA-T12D11/MA-T18A8-HRP and
MA-T30E5/MA-T17D7-HRP, respectively. The detection limit of all
three ELISAs was 1.6%. TAFI-depleted plasma revealed no detectable
response in any ELISA.
TAFI activity assay
The TAFI functional assay was performed essentially as described
elsewhere [19]. Brieﬂy, 100 μL of diluted plasma samples (20-fold
dilution of individual plasmas in TAFI-depleted pooled normal
plasma) were added to the wells of a microtitre plate containing
25 μL of a reaction mix composed of thrombin, Solulin (recombinant
thrombomodulin which was a gift from PAION GmbH, Aachen,
Germany (by courtesy of Dr. H. Brohmann)), CaCl2, and recombinant
tissue plasminogen activator (tPA) (Actilyse) (ﬁnal concentrations
in the assay: 3.3 NIH units mL-1, 2.0 μg/ml, 20 mM, 20 mM, and
0.10 μg mL-1, respectively), forming a plasma clot. A control with
addition of potato carboxypeptidase inhibitor (PCI) was performed
for each sample (ﬁnal concentration 30 μg mL-1). The wells were
immediately covered with parafﬁn oil and the plate was placed in
a pre-warmed (37 °C) incubation chamber of a microplate reader
(Victor3,™ multilabel counter, Perkin Elmer, Turku, Finland). The
optical density at 405 nm was monitored for 150 min. Lysis time (LT)
was deﬁned as the time-point corresponding to a 50% decrease in
optical density. Functional TAFI levels were calculated as TAFI-related
retardation (RT), deﬁned as the difference between the LT in the
absence and in the presence of PCI (LT-PCI - LT+PCI).
Using this assay the intra- and inter-assay variability of the TAFI-
related retardation of pooled normal plasma (20-fold diluted) were
7% and 13%, respectively (n=30; using several batches of TAFI-
depleted plasma) [19]. No inﬂuence was detected of the use of oral
anticoagulant therapy with vitamin K antagonists on functional TAFI
assay (data not shown).
Fibrinogen, CRP and vWF
Fibrinogen levels were determined according to the prothrombin
(PT)-derived method (Dade Thrombin Reagent, Siemens Diagnostics,
Leusden, The Netherlands) on a Sysmex CA-1500 automated coagu-
lation analyzer (Siemens Diagnostics, Leusden, the Netherlands).
When the PT or APTT was prolonged in patients, for instance due to
the use of oral anticoagulants, ﬁbrinogen concentrations were
determined according to the von Clauss method on an ACL-300
[HemosIL (Fibrinogen-C); Instrumentation Laboratory, Breda, the
Netherlands]. CRP levels were measured by means of an in-house
high-sensitive ELISA with polyclonal rat anti-human CRP antibodies
(DAKO, Glostrup, Denmark) and a CRP-calibrator (DAKO). VWF
antigen (vWF:Ag) was determined with an in-house ELISA with
polyclonal rabbit anti-human vWF antibodies and horseradish
peroxidase conjugated anti-human vWF (DakoCytomation, Glostrup,
Denmark) for catching and tagging, respectively. The intra-assay
variation coefﬁcient for vWF:Ag was 5.7%.
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The data are presented as means and standard deviations (SD) for
continuous variables and as counts and percentages for categorical
variables. To compare the plasma levels of TAFI variables between
the controls and the PAD patients an analysis of variance (ANOVA)
was used, with adjustment for age and gender. Spearman's correlation
coefﬁcient was calculated to study the associations between the
various TAFI antigen levels. The association between TAFI antigen
levels and PAD was investigated by logistic regression with TAFI
antigen as a continuous variable, with adjustment for age and gender.
In addition, we used a cut-off approach, in which the risk of PAD
in patients with high TAFI levels (top 10% based on distribution of
controls) was compared with risk of PAD in the remaining 90% of the
population, with adjustment for age and gender. A value of pb0.05
was considered statistically signiﬁcant. All statistical analyses were
performed using the Statistical Package for Social Science for
windows, version 16.0 (SPSS Inc., Chicago, IL, USA).Control Patient
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Fig. 1. TAFI antigen levels and functional TAFI levels in patients with PAD and healthy
controls.Results
The patient group consisted of 47 patients with a mean age of
43.2±7.9 years (range 21-55 years). The characteristics of the
patients and of the 141 individuals who served as a population-
based control group are summarized in Table 1. Most patients were
current or previous smokers (93.6%) and had a positive family
history of arterial thrombosis (63.8%) as well as other traditional
risk factors. BMI in patients was not signiﬁcantly higher in patients
(25.8±4.8 Kg.m-2) than in controls (25.5±4.5 Kg.m-2). All patients
had objectively diagnosed PAD and could be subclassiﬁed according
to the Rutherford criteria: 27 (57.4%) patients with claudication
(grade 2), 15 (31.9%) patients with ischemic rest pain (grade 3) and
5 (10.6%) patients with tissue loss (grade 4).
Intact TAFI antigen levels were signiﬁcantly higher in patients with
PAD (112.4±21.1%; mean±SD) versus healthy controls (104.9±
19.9%; p=0.03) (Fig. 1). The risk of PAD increased with 18% (OR 1.18;
CI 1.01-1.35) per 10% increase of TAFI antigen. TAFI activation peptide,
a marker for TAFI activation in vivo, was not signiﬁcantly different
from the controls, nor were the levels of activated and inactivated
TAFI (TAFI a(i)) (Table 2).Table 1
Characteristics of PAD patients and healthy controls.
Patients
(n=47)
Controls
(n=141)
p value
Demographics
Age – years
Mean 43.2±7.9 43.0±7.6 0,85
Male sex – n (%) 13 (27.7) 39 (27.7) 0.94
Oral anticoagulant use – n (%) 13 (27.7) 2 (1.4) b0.0001
Risk Factors
Family history of premature
cardiovascular disease – n (%)
30 (63.8) 47 (33.3) b0.0001
Hypercholesterolemia – n (%) 22 (46.8) 6 (4.3) b0.0001
Hypertension – n (%) 18 (38.3) 10 (7.1) b0.0001
Diabetes mellitus – n (%) 10 (21.3) 1 (0.7) 0.001
Smoking status – n (%)
Never smoked 3 (6.4) 60 (42.6) b0.0001
Former smoker 21 (44.7) 46 (32.6) b0.0001
Current smoker 23 (48.9) 35 (24.8) b0.0001
Clinical aspects
Body-mass index (kg/m2) 25.8±4.8 25.5±4.5 NS
Rutherford criteria – n (%)
Asymptomatic (Grade 1) 0 141
Claudication (Grade 2) 27 (57.4) -
Ischemic rest pain (Grade 3) 15 (31.9) -
Tissue loss (Grade 4) 5 (10.6) -
NS=not signiﬁcant.Functional TAFI was measured as TAFI-related retardation in a
plasma clot lysis based assay. Functional TAFI was not signiﬁcantly
higher in patients compared to controls (17.4±3.0 min vs. 16.7±
2.4 min; p=0.28, respectively) (Fig. 1). To further investigate
whether increased functional TAFI levels are a risk factor for PAD
we calculated odds ratios using different cut-off percentiles of
functional TAFI, based on the levels in the control group. Individuals
with functional TAFI levels in the highest 10% percentile showed
an increased risk of PAD compared to individuals in the lowest 90%
percentile (OR 3.1; 95% CI 1.02-9.41).
No relationships between TAFI activation peptide and TAFI a(i)
with PAD were observed in our study (Table 2). Functional TAFI was
signiﬁcantly correlated with TAFI activation peptide (r=0.19,
p=0.047), but not with TAFI antigen levels and TAFIa(i) (Table 3).Table 2
Laboratory parameters in PAD patients and healthy controls.
Patients
(n=47)
Controls
(n=141)
p value
TAFI parameters
TAFI antigen (%) 112.4±21.1 104.9±19.9 0.03
TAFI activation peptide (%) 140.9±38.0 145.3±52.5 0.58
TAFI a(i) (%) 139.3±36.3 137.1±34.2 0.71
Functional TAFI
[TAFI-related retardation] (min)⁎
17.4±3.0 16.7±2.4 0.28
Haemostatic/inﬂammatory parameters
Fibrinogen (g/L) 4.07±0.85 3.39±0.96 b0.001
vWF:Ag (U/mL) 1.47±0.52 1.03±0.38 b0.001
hsCRP (mg/L) 3.29±4.58 1.56±3.58 0.006
⁎ The TAFI functional assay was measured as TAFI-related retardation and expressed
in minutes (mean±SD).
Table 3
Relationship between the various TAFI antigen levels in PAD patients and healthy
control individuals.
TAFI
Ag
TAFI AP TAFI a(i) TAFI-related
retardation
Fibrinogen vWF:
Ag
hsCRP
TAFI Ag 0.39 0.15 0.16 0.17 0.13 0.06
p value b0.0001 0.04 0.10 0.07 0.07 0.43
TAFI AP 0.26 0.19 0.05 0.03 0.05
p value b0.0001 b0.05 0.61 0.67 0.50
TAFI a(i) -0.02 -0.09 0.05 -0.01
p value 0.80 0.32 0.50 0.93
TAFI-related
retardation
0.17 0.10 0.17
p value 0.07 0.30 0.08
Correlations (non-parametric, Spearman 2-tailed).
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TAFI activation peptide levels (r=0.39, pb0.0001) and between TAFI
activation peptide levels and TAFI a(i) (r=0.26, pb0.0001).
Fibrinogen, hsCRP and vWF antigen levels were signiﬁcant higher
in patients with PAD versus healthy controls. Mean ﬁbrinogen levels
were 4.07±0.85 g/L in PAD patients versus 3.39±0.96 g/L (pb0.001)
in healthy controls. Mean hsCRP levels were 3.29±4.58 mg/L in PAD
patients versus 1.56±3.58 mg/L (p=0.006) in healthy controls.
Mean vWF:Ag levels were 1.47±0.52 U/ml in PAD patients versus
1.03±0.38 U/ml (pb0.001) in healthy controls.
Discussion
We studied for the ﬁrst time TAFI levels in a well deﬁned group of
patients with peripheral arterial disease at young age. We showed
that high TAFI levels are associated with increased risk of PAD. This is
in line with previous reports that increased TAFI levels are associated
with other forms of arterial thrombosis, i.e. ischemic stroke [11,12].
Previous studies have indicated that hypoﬁbrinolysis may be
associated with increased risk of arterial thrombosis including
coronary heart disease, ischemic stroke and PAD, although this was
not conﬁrmed in all studies [3,4,20–25]. This increased risk hasmainly
been attributed to increased levels of plasminogen activator inhibitor-1
[4]. In addition, it has been suggested that the PAI-1 -675(4 G/5 G)
polymorphism is associated with the outcome of PAD [6].
TAFI is an important inhibitor of ﬁbrinolysis, by cleaving the lysine
binding sites of partially degraded ﬁbrin, which interferes with the
interaction of plasminogen with ﬁbrin. High TAFI levels may therefore
result in a decreased ﬁbrinolytic activity [9,10]. Several studies have
been performed to assess the relationship between TAFI levels and the
risk of arterial thrombosis. In previous studies, we and others have
found that functional TAFI levels are signiﬁcantly associated with the
risk of ﬁrst ischemic stroke [11,26]. Also TAFI antigen levels have been
associated with ischemic stroke, (unstable) angina pectoris and acute
myocardial infarction [11,13,27–29]. Previous studies were hampered
by the fact that most antigen assays are highly sensitive to the
TAFI genotype, which inﬂuences the outcome of some of the early
studies (reviewed in [22]). Recently, we have developed genotype-
independent TAFI antigen assays, and we were able to analyze TAFI
antigen levels using three newly developed immunological assays
with distinct reactivities towards TAFI and TAFI fragments [18]. These
assays measure intact TAFI, the released activation peptide (TAFI-AP)
and the total of activated and inactivated TAFI. So far these assays have
only been used to study TAFI levels in acute ischemic stroke, coronary
heart disease and severe meningococcal infection [12,15,30,31]. In
acute ischemic stroke, it was shown that both intact TAFI and the
activation peptide were increased in patients compared to healthy
controls [12]. We previously showed that TAFIa(i) levels were higher
in young patients with cardiovascular disease in our ATTAC study[15]. In patients with coronary artery disease in the AtheroGene study
the amount of activated TAFI, measured by TAFIa/TAFIai ELISA was
independently associated with increased risk of cardiovascular death
[30]. In severe meningococcal infection in children intact TAFI and the
activation peptide were also signiﬁcantly increased [31].
We have studied young patients with PAD, because it is suggested
that in these young patients other pathogenetic mechanisms than
the classical risk factors may be of importance [4,32]. Patients were
included one to three months after the ﬁrst ischemic event to exclude
an acute phase response, although previous studies have suggested
that the relationship between TAFI levels and arterial thrombosis is
both seen in the acute phase and at three-months follow-up [11,12]. In
our study, TAFI antigen levelswere signiﬁcantly higher in PADpatients
than in the healthy controls. TAFI-AP levels and TAFIa(i) levels were
not higher in PAD patients. Since TAFI-AP is a marker of the extent of
TAFI activation, this suggests that TAFI activation is not systemically
increased in PAD patients.
Wemeasured functional TAFI levels using apreviouslydescribed clot
lysis based method. By measuring clot lysis time with and without
a speciﬁc inhibitor of TAFI (PCI) the functional activity of TAFI can be
determined. Furthermore, a clot lysis basedassay is amorephysiological
method than assays using chromogenic substrates to study the impact
of TAFI on ﬁbrinolysis [19]. A trend was seen for higher functional TAFI
activity in PAD patients compared to controls, but this did not reach
statistical signiﬁcance. Individuals with functional TAFI levels above the
90th percentile however had an increased risk of PAD.
We also studied other haemostatic variables (Fibrinogen and
vWF:Ag levels) and a marker of inﬂammation (hsCRP), which are of
importance as risk factors in the development of PAD [33], in relation
to TAFI. Fibrinogen, hsCRP and vWF were all signiﬁcantly elevated
in PAD patients in comparison to the healthy controls. However,
the correlation between TAFI antigen with ﬁbrinogen, vWF Ag and
CRP was very weak. This suggests that the association between TAFI
and PAD is independent of an inﬂammatory status or endothelium
damage. Prospective studies are needed to investigate the association
betweenTAFI levels and cardiovasculardisease as, on theonehand, high
TAFI levels may facilitate the development of cardiovascular comorbid-
ity by shifting the haemostatic balance to a more hypoﬁbrinolytic state
and, on the other hand, TAFI levelsmay relate to the body'smechanisms
dampening the excessive inﬂammatory reaction, such as previously
found in patients with rheumatoid arthritis [34,35]. Growing evidence
suggests that inﬂammation, oxidative stress and hypoﬁbrinolysis may
have a pivotal role in the high prevalence of cardiovascular disease [36].
Our study has some important strengths. We measured TAFI
antigen levels using three recently developed TAFI assays that are
independent of TAFI genotypes. These assays make it possible to
determine not only intact TAFI levels, but also provide information on
TAFI activation. In addition,we havemeasured functional TAFI activity.
A limitation is the small size of our group of PADpatients. Only patients
with a ﬁrst clinical manifestation of peripheral arterial disease at
young age were included. The statistically signiﬁcant difference that
we observed does not automatically mean that our ﬁndings are also of
clinical relevance. Whether there is a role for TAFI in determining the
outcomeof PADwasnot the aimof our study andneeds to be studied in
large, prospective studies. We selected our patients and controls from
the same population (controls were friends of the patients), which
eliminates part of the potential patient-control differences, but that
remaining differences between patients and controls may contribute
to our ﬁndings.
In conclusion, our study, although carried out in a small group of
patients, shows for the ﬁrst time that increased levels of TAFI are
associated with risk of premature peripheral arterial disease.
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